LimFlow
LimFlow is a private, venture-backed medical device company transforming the treatment of Critical Limb Ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease and an aging population. The LimFlow Percutaneous Deep Vein Arterialization (pDVA) System is designed to bypass blocked arteries in the leg and rush oxygenated blood back into the foot. For many patients, restoring perfusion in the lower limbs resolves chronic pain, improves quality of life, promotes wound healing and prevents major amputation.
Sector
Medical Devices
Strategies
MD Start & Crossover
Status
Exit
Website
limflow.com
Kinam Hong
Partner, Sofinnova Partners - Crossover Strategy
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Related News
LimFlow announces agreement to be acquired by Inari Medical
Landmark New England Journal of Medicine publication reports positive results from PROMISE II pivotal trial showing that LimFlow System saves most patients with end-stage peripheral artery disease from major amputation
LimFlow raises $40 million (€36 million) in Series D financing
Limflow raises €27 million ($33.5 million) in Series C financing led by Sofinnova Partners to advance innovative critical limb ischemia (CLI) treatment
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.